<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="102401">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01763060</url>
  </required_header>
  <id_info>
    <org_study_id>Dnr 2012/986-31/3</org_study_id>
    <secondary_id>Long term outcome</secondary_id>
    <nct_id>NCT01763060</nct_id>
  </id_info>
  <brief_title>Long Term Follow up of Patients Who Were Treated With Extracorporeal Membrane Oxygenation for Pandemic Influenza A/H1N1 Induced Severe Respiratory Failure</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Uppsala University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <authority>Sweden: Regional Ethical Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients treated with Extracorporeal Membrane Oxygenation (ecmo) for severe respiratory or
      circulatory failure show severe long term disability due to  impaired lung -, cerebral-,
      cognitive function and impaired quality of life. This study investigates the long term
      outcome of all patients who are still alive three years after ECMO treatment for severe
      respiratory failure during the H1N1 2009 pandemic at the Karolinska University Hospital.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Cross-Sectional</study_design>
  <primary_outcome>
    <measure>Lung function</measure>
    <time_frame>3 years after ecmo treatment</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">7</enrollment>
  <condition>Long Term Outcome</condition>
  <arm_group>
    <arm_group_label>ECMO survivors</arm_group_label>
    <description>CT scan of the chest of all ECMO survivors after 2009/2010 pandemics Tests for cognitive function MRI of the brain Lung function</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>CT scan</intervention_name>
    <arm_group_label>ECMO survivors</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive function</intervention_name>
    <arm_group_label>ECMO survivors</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>MRI</intervention_name>
    <arm_group_label>ECMO survivors</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients who survived ECMO treatment due to infection with Influenza A/H1N1 2009 up to
        3 years after discharge from hospital
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Survivors of ECMO treatment for influenza a/h1n1 pneumonia during 2009/2010 pandemics
             at the ECMO Center Karolinska

        Exclusion Criteria:

          -  None
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 20, 2013</lastchanged_date>
  <firstreceived_date>January 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Bernhard Holzgraefe</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>ards</keyword>
  <keyword>ecmo</keyword>
  <keyword>h1n1</keyword>
  <keyword>pandemics</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
